Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) today reported completion of patient enrollment in a dose confirmation and dosimetry trial of Cotara ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE